欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2024, Vol. 29 ›› Issue (5): 495-500.doi: 10.12092/j.issn.1009-2501.2024.05.003

• 子宫内膜异位症药物治疗最新研究进展 • 上一篇    下一篇

1例烟雾病合并子宫内膜异位症患者围手术期抗血小板药物调整及术后预防内异症复发药物选择的病例分析

罗莉婷1,2,金经1   

  1. 1复旦大学附属妇产科医院药学部,上海 200090;2珠海市妇幼保健院药学部,珠海 519000,广东
  • 收稿日期:2023-08-22 修回日期:2023-10-03 出版日期:2024-05-26 发布日期:2024-04-16
  • 通讯作者: 金经,女,硕士研究生,主管药师,研究方向:医院药学。 E-mail: szjj1988@163.com
  • 作者简介:罗莉婷,女,硕士研究生,主管药师,研究方向:医院药学。 E-mail: erin1101@163.com
  • 基金资助:
    2021年上海市“医苑新星”青年医学人才培养资助(076478684Q/2022-00033)

A case analysis of medication adjustments on a moyamoya disease patient with endometriosis by DAPT treatment during perioperative period and formulation of DIE postoperative recurrence prevention

LUO Liting1,2, JIN Jing1   

  1. 1 Department of Pharmacy, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200090, China; 2 Department of Pharmacy, Zhuhai Center for Maternal and?Child Health Care, Zhuhai?519000, Guangdong China
  • Received:2023-08-22 Revised:2023-10-03 Online:2024-05-26 Published:2024-04-16

摘要:

目的:探讨临床药师在烟雾病患者围术期个体化治疗与用药监护中的工作要点。方法:参与1例烟雾病合并子宫内膜异位症患者围术期双联抗血小板治疗的药物调整、围术期应用质子泵抑制剂及深部子宫内膜异位症术后预防复发方案的制订与用药监护。结果:通过对患者的个体化评估确定符合患者的双联抗血小板治疗在围术期停药方案,制订个体化的围术期应用质子泵抑制剂及深部子宫内膜异位症术后预防复发方案。结论:个体化用药方案的制订及用药监护是临床药师开展药学服务的切入点。

关键词: 烟雾病, 子宫内膜异位症, 双联抗血小板, 预防复发

Abstract:

AIM: To explore the key points of personalized treatment and medication monitoring by clinical pharmacists in the perioperative period of moyamoya disease patients with endometriosis. METHODS: This study showed a moyamoya disease patient with endometriosis who accepting dual antiplatelet therapy and how to adjust medication during the perioperative period. Besides, monitoring the use proton pump inhibitors in the perioperative period and the formulating a plan of DIE postoperative recurrence prevention are also our objectives. RESULTS: Through individualized assessment of the patient, a personalized medication adjustments for dual antiplatelet therapy was determined. Individualized perioperative proton pump inhibitor regimen and postoperative prevention plan for endometriosis recurrence were developed. CONCLUSION: The development of individualized medication regimens and medication monitoring is the breakthrough point for clinical pharmacists to carry out pharmaceutical services.

Key words: moyamoya disease, endometriosis, DAPT, preventing recurrence

中图分类号: